Literature DB >> 11412216

Consensus development of a histopathological classification system for chronic prostatic inflammation.

J C Nickel1, L D True, J N Krieger, R E Berger, A H Boag, I D Young.   

Abstract

OBJECTIVE: To develop a standardized histopathological classification system for chronic prostatitis (standardized description of prostatic inflammatory infiltrates) based on a literature review, extensive prospective evaluations in two recognized prostatitis research centres and widespread consensus of international urological centres identified as having major expertise or interest in chronic prostatitis.
METHODS: Relevant articles for review were identified by a Medline search undertaken by the Cochrane Review Group in Prostate Diseases and Urologic Malignancies, and cross-checking bibliographies of retrieved studies, reviews, book chapters and abstracts of the American Urological Association and International Prostatitis Collaborative Network Annual Meetings. Initial drafts were based on classification systems independently developed by the Prostatitis Research Centers at Queen's University in Canada and University of Washington in the USA. A collaborative draft was distributed to 20 urological/pathological clinical centres who participated in the North American Chronic Prostatitis Collaborative Research Network and First International Prostatitis Collaborative Network. A consensus classification system was then distributed to the participating panel for acceptance.
RESULTS: The literature review identified a reasonably consistent description of inflammatory infiltrate locations and patterns that were further incorporated into the draft based on the Queen's University and University of Washington proposals. Eighteen (90%) of the identified Prostatitis Centers participated in the revision of the draft and the final consensus process. The final consensus document classifies prostatic inflammation according to its extent and grade/severity in each tissue compartment (location). Conclusion The consensus of the expert panel was that this classification system can be used in the evaluation of prostatic inflammation in prostate biopsies, transurethral resected prostate chips or prostatectomy specimens. A standardized accepted framework to describe histopathological prostate inflammation will prove useful in evaluating prostate disease.

Entities:  

Mesh:

Year:  2001        PMID: 11412216     DOI: 10.1046/j.1464-410x.2001.02193.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  64 in total

1.  Uropathogenic Escherichia coli induces chronic pelvic pain.

Authors:  Charles N Rudick; Ruth E Berry; James R Johnson; Brian Johnston; David J Klumpp; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Infect Immun       Date:  2010-11-15       Impact factor: 3.441

2.  Racial differences in the relationship between clinical prostatitis, presence of inflammation in benign prostate and subsequent risk of prostate cancer.

Authors:  B A Rybicki; O N Kryvenko; Y Wang; M Jankowski; S Trudeau; D A Chitale; N S Gupta; A Rundle; D Tang
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-12-01       Impact factor: 5.554

3.  [Modification of the histopathologic degree of inflammation in asymptomatic prostatitis (NIH IV) by moxifloxacin].

Authors:  T Bschleipfer; F M E Wagenlehner; W Weidner
Journal:  Urologe A       Date:  2007-09       Impact factor: 0.639

4.  Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients.

Authors:  Pradeep Tyagi; Saundra S Motley; Tatsuki Koyama; Mahendra Kashyap; Jeffrey Gingrich; Naoki Yoshimura; Jay H Fowke
Journal:  Prostate       Date:  2017-10-27       Impact factor: 4.104

Review 5.  Surgical therapy of prostatitis: a systematic review.

Authors:  Dominik S Schoeb; Daniel Schlager; Martin Boeker; Ulrich Wetterauer; Martin Schoenthaler; Thomas R W Herrmann; Arkadiusz Miernik
Journal:  World J Urol       Date:  2017-06-13       Impact factor: 4.226

6.  Uropathogenic Escherichia coli-induced fibrosis, leading to lower urinary tract symptoms, is associated with type 2 cytokine signaling.

Authors:  Ashlee Bell-Cohn; Daniel J Mazur; Christel Hall; Anthony J Schaeffer; Praveen Thumbikat
Journal:  Am J Physiol Renal Physiol       Date:  2019-01-09

7.  Intraprostatic inflammation is positively associated with serum PSA in men with PSA <4 ng ml(-1), normal DRE and negative for prostate cancer.

Authors:  M H Umbehr; B Gurel; T J Murtola; S Sutcliffe; S B Peskoe; C M Tangen; P J Goodman; I M Thompson; S M Lippman; M S Lucia; H L Parnes; C G Drake; W G Nelson; A M De Marzo; E A Platz
Journal:  Prostate Cancer Prostatic Dis       Date:  2015-05-05       Impact factor: 5.554

Review 8.  Benign Prostatic Hyperplasia and Lower Urinary Tract Symptoms: What Is the Role and Significance of Inflammation?

Authors:  Granville L Lloyd; Jeffrey M Marks; William A Ricke
Journal:  Curr Urol Rep       Date:  2019-08-03       Impact factor: 3.092

Review 9.  MSMB variation and prostate cancer risk: clues towards a possible fungal etiology.

Authors:  Siobhan Sutcliffe; Angelo M De Marzo; Karen S Sfanos; Martin Laurence
Journal:  Prostate       Date:  2014-01-24       Impact factor: 4.104

10.  Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer?

Authors:  Nicolas B Delongchamps; Gustavo de la Roza; Vishal Chandan; Richard Jones; Robert Sunheimer; Gregory Threatte; Mary Jumbelic; Gabriel P Haas
Journal:  J Urol       Date:  2008-03-17       Impact factor: 7.450

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.